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Abstract
Background: Cystic Fibrosis (CF) Centers are involved in the decisions regarding the eligibility of CF patients with
end-stage lung disease and timing for inclusion on waiting lists (WL) for lung transplantation (LT). There are
currently no data on the mortality rates of Italian CF patients on WL and during the first year after LT and we aimed
to assess these outcomes by surveying the CF Centers.
Methods: A survey was sent to Italian CF Centers which were requested to report the age at which all CF subjects
included on the WL between 2010 and 2014 were included on the list, admitted to either standard or urgent LT, or
had died either while on the WL or within the first 3 and 12 months after LT. All outcomes were recorded by
December 31, 2015.
Results: Two hundred fifty-nine CF subjects were included on the WL during the 5-year study period. The mortality
rate during the WL was 19.3% and was not associated with sex, age at inclusion on the WL or standard or urgent
access to LT. 159 (61.4%) subjects underwent LT, 46 (28.9%) with urgent procedure. Deaths within the first 3 and
12 months after LT were significantly more prevalent in individuals who underwent urgent LT compared to those
with standard LT (p < 0.01).
Conclusions: The mortality of Italian CF patients, included in our survey, was about twice that reported by the
National Transplant Center for all LT indications, including CF, during the same time period and despite the
introduction of urgent LT. The latter was associated with an unfavorable early outcome compared to standard LT.
Background
Lung transplantation (LT) is offered to subjects with
cystic fibrosis (CF) with end-stage lung disease as a po-
tential life-extending and life-improving treatment [1, 2].
Different predictive models for mortality have been pro-
posed but the optimal timing for listing of CF individ-
uals for LT is a complex task for the CF specialist [3–5].
In addition to measures which attempt to deal with
the shortage of suitable lung donors, different organ
allocation policies, based on medical urgency, have been
proposed to avoid long waiting times and death either
while on the waiting list (WL) or during the first year after
LT. The lung allocation score (LAS) was implemented to
prioritize patients in the United States [6]. Dedicated
emergency LT procedures have been proposed as strat-
egies in France and Italy for patients in extremely urgent
medical conditions, such as those requiring mechanical
ventilation (MV) or extracorporeal membrane oxygen-
ation (ECMO) [7–10]. The urgent LT procedure is pro-
posed only for patients already wait-listed in Italy [9, 10].
In France the “high emergency waiting list” is proposed
for patients with an abrupt worsening of their respiratory
function, requiring invasive mechanical ventilation (MV)
and/or ECMO or who are at risk of imminent invasive
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MV or of having severe pulmonary hypertension [7, 8].
The inclusion on the regular waiting list was not an inclu-
sion criterion in France, as recorded for 51.5% of patients
in a recent nation-based study [8].
Italian CF Centers are involved in LT programs, by
determining the timing for inclusion on the WL and by
caring for patients while they await surgery. Listing
criteria were the same as those suggested in the inter-
national literature [1, 2].
Due to the lack of data on the mortality rate of Italian
CF subjects on the WL and during the first year after
LT, we surveyed these outcomes, as recorded by Italian
CF Centers.
Methods
This retrospective cross-sectional survey included 22
Italian CF Centers. All CF subjects were referred to CF
Centers to assess the timing for their inclusion on the WL
and optimize their medical treatment during their wait.
They were then referred to the Lung Transplant Centers,
which established their eligibility for LT and inclusion on
the WL. According to the Italian Cystic Fibrosis Register
(ICFR) Report 2010, our survey addressed 4159 children
and adult CF patients in 2010 [11].
CF Centers were asked to record all WL subjects be-
tween 2010 and 2014. The survey covered the following
demographic and outcome data: year of inclusion on the
WL, sex, age at inclusion on the WL, age at time of
standard or urgent LT, age at time of death occurring ei-
ther while on the WL or within 3 and 12 months after
transplant. The outcomes were considered as of Decem-
ber 31, 2015.
CF Centers were requested to review systematically
the medical records of all subjects included on the WL
to avoid missing data. According to our aims, we chose
to collect data only on mortality before and during the
first year after LT.
Eleven Lung Transplant Centers were active in Italy in
the period 2010–2014 [12]. In October 2010, under the
supervision of the National Transplant Center, all Lung
Transplant Centers created and agreed on a common
protocol to identify patients requiring lung transplant
priority [9, 10]. The Italian Urgent Lung Transplant pro-
gram (IULTp) is reserved for patients younger than
50 years, who moved from the standard lung transplant
program to urgent LT, if they required mechanical venti-
lation and/or extracorporeal lung support. Exclusion cri-
teria are sepsis, multiorgan failure, hemorrhagic shock,
neurological damage and invasive respiratory support
lasting more than 14 days. Since 2010 both the standard
LT program and the IULTp have been active in Italy.
Priority of the IULTp can last 3 weeks. All available
lungs in the country must be considered for urgent
transplant first.
The yearly number of LTs, deceased patients on wait-
ing lists and patients still on the WL for all LT indica-
tions, including patients with CF, are recorded in the
Reports of the National Transplant Center [12]. Data on
single LT indications and LT modality (single/bilateral/
heart-lung) are not available.
We considered also the number of LTs and age at the
surgical procedure recorded by the ICFR in Italy during
2010–2014, to compare these data with those of the CF
subjects included in our study [11, 13]. The ICFR did
not collect clinical data of CF individuals at time of in-
clusion on the WL, during the waiting time, at the time
of transplantation, during the perioperative period or in
the follow-up after the LT.
The study protocol was approved by the Ethics Com-
mittee of the Hospitals involved in the survey.
Descriptive statistics and comparisons between groups
for continuous variables were performed according to nor-
mal distribution tests. Kruskal-Wallis analysis of variance
was used to compare variables among three groups of in-
dividuals according to their age. The Mann-Whitney test
was used to compare demographic data and outcomes of
subjects listed in the standard versus the urgent LT
programs.
Differences in proportions of categorical data were
assessed using the Chi-square test. Statistical significance
was defined as p < 0.05.
Results
16/22 (72.7%) CF Centers sent data on CF individuals
included on the WL during the 5-year study period. The
survey covered 82.4% of subjects included in the 2010
ICFR Report [11].
Two hundred fifty-nine subjects were included on the
WL: the median (interquartile range) age was 30.4
(22.1–37.5) years (Table 1). Three subjects were removed
from the WL because of improved clinical condition
after 2.1, 0.8 and 0.8 years, respectively. Two subjects,
retransplanted during the study period, were considered
only for their first LT. We recorded 50 deaths (19.3%)
during patients’ time on the WL, 159 lung transplants
(61.4%) and 47 (18.1%) subjects still on the WL at
December 31, 2015 (Table 1).
CF individuals were grouped by age into three groups
at the time of inclusion on the WL, with the aim of
comparing outcomes between pediatric patients, young
adults and subjects older than 30 years. Table 1 shows
that more females were recorded among pediatric sub-
jects compared to adults either younger or older than
30 years, but the difference was not statistically signifi-
cant (p = 0.061). There were no statistically significant
differences in number of deaths, LTs, subjects still on
the WL, and duration of WL between deceased and
transplanted subjects in the three groups. The waiting
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time of deceased subjects on the WL was not different
from that of transplanted subjects (Table 1).
Table 2 compares demographic data and outcomes of 57
individuals listed in the IULTp to 202 patients listed only
in the standard LT program. There were no differences in
sex, age at inclusion on the WL and mortality rate during
WL between the two groups. The percentage of subjects
who waited less than 3 months for surgery was significantly
different in the two groups (43.9% vs 3.5%: p < 0.001).
Deaths within 3 and 12 months were more frequent in
subjects who required an urgent procedure compared
to those undergoing standard LT (19.3 and 24.6% vs
6.4 and 8.9%, p < 0.01 and p < 0.01, respectively).
The National Transplant Center reported 107 LTs in
2010, 120 in 2011, 114 in 2012, 141 in 2013 and 126 in
2014, including single, bilateral and heart-lung LTs. The
mean mortality of those patients on the WL was 11.5%
in 2010, 10.2% in 2011, 12.1% in 2012, 10.9% in 2013
and 9.3% in 2014 for all indications for LT [12].
The ICFR reported that there were 20 LTs in CF
patients in 2010, 36 in 2011, 25 in 2012, 40 in 2013 and
34 in 2014 [11, 13]. According to the Reports of the Na-
tional Transplant Center, the primary disease of 155/608
transplant recipients was cystic fibrosis (25.5%) [11–13].
Data on mortality of patients on the WL, number of
either urgent or standard LTs, data on mortality after LT
were not reported by the ICFR [11–13].
Discussion
The major findings of our study are the 19.3% mortality
rate of those CF patients on the WL and the less favor-
able outcome soon after LT of those patients who
Table 1 Characteristics and outcomes of 259 subjects with cystic fibrosis included on the waiting list for lung transplantation during
2010-2014a
All Age (yrs)
< 17.9 18–29.9 ≥ 30
No. 259 38c 88 133d
Age at inclusion on WL (yrs)b 30.4 (22.1–37.5) 15.3 (12.5–17.0) 24.4 (21.8–26.1) 37.0 (33.7–42.0)
Females: No. (%) 148 (57.1) 27 (71.1) 49 (55.7) 72 (54.1) p = 0.061
Deaths on WL: No. (%) 50 (19.3) 9 (23.7) 14 (15.9) 27 (20.3) p = 0.548
Waiting time of deceased subjects (yrs)b 0.8 (0.2–1.2) 0.9 (0.2–1.9) 0.5 (0.1–1.2) 0.8 (0.4–1.3) p = 0.639
LTs: No. (%) 159 (61.4) 24 (63.2) 55 (62.5) 80 (60.2) p = 0.913
Waiting time of transplanted sub-jects (yrs)b 0.9 (0.3–1.8) 0.8 (0.5–1.3) 0.8 (0.2–1.9) 1.0 (0.4–1.9) p = 0.514
Still on WL: No. (%) 47 (18.1) 3 (7.9) 19 (21.6) 25 (18.8) p = 0.180
WL waiting list, LT lung transplantation
aoutcomes were considered until December 31, 2015
bdata are reported as median and interquartile range
ctwo subjects were removed from the WL after 2.1 and 0.8 years
done subject was removed from the WL after 0.8 years
Table 2 Comparison of demography and outcomes between subjects listed for urgent lung transplantation program and those
listed for standard lung transplantation programa
Urgent lung transplantation program Standard lung transplantation program
No. 57 202c
Females: No. (%) 34 (59.6) 114 (56.4) p = 0.665
Age at inclusion on WL (yrs)b 27.6 (23.4–36.7) 30.5 (21.8–37.6) p = 0.826
Deaths on WL: No. (%) 11 (19.3) 39 (19.3) p = 0.998
Waiting time of deceased subjects (yrs)b 0.4 (0.2–0.9) 0.8 (0.3–1.4) p = 0.127
LTs: No. (%) 46 (80.7) 113 (55.9) p < 0.001
Waiting time of transplanted subjects (yrs)b 0.2 (0.1–1.0) 1.0 (0.6–1.9) p < 0.001
Subjects waiting less than 3 months before LT: No. (%) 25 (43.9) 7 (3.5) p < 0.001
Transplanted subjects deceased during the first 3 months
after LT: No. (%)
11 (19.3) 13 (6.4) p < 0.01
Transplanted subjects deceased during the first 12 months
after LT: No. (%)
14 (24.6) 18 (8.9) p < 0.01
WL waiting list, LT lung transplantation
aoutcomes were considered until December 31, 2015
bdata are reported as median and interquartile range
cthree subjects were removed from the WL after 2.1, 0.8 and 0.8 years
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underwent urgent LT, when compared with those under-
going standard procedure.
The introduction of LAS in the USA has helped to re-
duce the mortality rate for CF patients on the WL from
22 to 29 to 12.9% and benefited survival after LT in re-
cipients with CF [5, 6, 14–16]. Preliminary reports have
recorded a decrease in mortality of CF patients on WL
from 22.1 to 13.7%, comparing 1-year before and after
introduction of LAS in Germany in 2011 [17].
Both dedicated emergency programs in France and
Italy were associated with a decrease in mortality of pa-
tients on the WL for all indications: in France from 8.6%
in 2006 to 3.5% in 2011, in Italy from a range of 11.5–
14.7% during 2005–2009 to a range of 9.3–12.1% during
2010–2014 [8–10, 12]. Unfortunately, data about out-
comes of different underlying lung diseases is not avail-
able in Italy. The mortality rate of CF subjects on the
WL in our study remained high, being nearly double
that recorded for all indications for LT, including CF, in
the same time period, during which the urgent proced-
ure was implemented [15]. The findings on mortality
rate in CF may suggest that a different organ allocation
policy should be considered in Italy to improve survival
for subjects with cystic fibrosis who are on the WL and
for those who receive lung transplantation.
A late inclusion in WL and therefore a poor selection
of CF patients should be unlikely for the standard LT,
since we found that the waiting time was similar in de-
ceased and transplanted individuals. Inclusion and exclu-
sion criteria on the WL were not different from those
reported in the literature [1, 2]. However, we found that
the waiting time of subjects undergoing urgent LT was
significantly less compared to those undergoing standard
LT. A waiting time of less than 3 months was recorded
in 43.9% of subjects who were moved from standard to
urgent LT. An unpredictable, rapid decline in lung func-
tion can occur in some patients with CF and moving
from standard to urgent LT represents the only oppor-
tunity for a lung transplant in these patients.
Donor shortage and the inadequate number of LTs are
also reasons for mortality rates in CF patients waiting
for a transplant. The ratio between number of LTs and
number of subjects on the active WL was 312/490 (0.64)
in France, 327/581 (0.56) in Germany and 120/561
(0.21) in Italy in 2011: these figures were associated with
different WL durations [8–10, 12, 17, 18].
For patients who moved from standard to urgent LT,
IULTp resulted in LT in 80.7% of the cases and should be
considered an efficient strategy, considering that mortality
while on the WL (19.3%) was the same as that for patients
in the standard program (19.3%). The IULTp therefore of-
fered an opportunity for LT to seriously ill CF patients
who would have otherwise died while on the WL. How-
ever, the IULTp was associated with increased mortality
within the first year after LT. The urgent LT program in
France showed similar results: the overall in-hospital mor-
tality rate was 29.4% for 95 transplanted subjects, with
extracorporeal membrane oxygenation (ECMO) prior to
LT being the sole independent mortality risk factor [8].
The high mortality associated with IULTp should be inter-
preted cautiously in the context of the most critical condi-
tions in which it was used. A high LAS score was also
associated with an increased risk of death after LT in cys-
tic fibrosis patients [19]. Prospective research is needed to
assess whether timing, duration and modality of ECMO
and associated invasive respiratory support could be
modified to decrease the mortality rate after LT.
The main limitation of our survey is that we included
only data on the mortality rate of CF patients on the
WL and during the first year after LT. We did not rec-
ord the clinical characteristics of CF individuals at the
time of inclusion on the WL, the deterioration of lung
disease during the waiting time, lung donor characteris-
tics, the modality and duration of invasive support for
patients in the urgent program before and after LT, all of
which are risk factors affecting survival before and after
LT [1–5, 8, 14, 15]. Many of these clinical data were re-
corded by the Transplant Centers, but were not included
in our survey. Neither the ICFR nor the National Trans-
plant Center collected or reported this important clinical
information. The ICFR recently reported that 10% of
transplanted subjects had missing data on outcomes
after LT [13]. Probably some patients were followed up
only by the Transplant Centers once they received a LT.
A prospective study should be designed which involves
both CF Centers and Lung Transplant Centers to collect
clinical data for assessing which risk factors affect sur-
vival before and after LT.
Our survey covered 82.4% of CF subjects in Italy during
our study period and our mortality rates could be under-
estimated. The ICFR recently reported that 155 CF pa-
tients received a LT in the same 5-year period [11, 13].
Our study reported 159 LTs for 259 subjects included on
the WL. Although a bias of missing data cannot be
excluded, our study recorded mortality data of all 259 sub-
jects included on the WL between 2010 and 2014.
Conclusions
In conclusion, despite some limitations, this study is the
first attempt to evaluate mortality of Italian CF patients
while they are on the waiting list for lung transplantation
and within 3 and 12 months after they have received ei-
ther urgent or standard LTs. In spite of the introduction of
emergency LT in Italy, the mortality rate of CF patients on
the WL was twice that for all LT indications, including CF,
and higher than that recorded in other countries for the
same disease. The urgent procedure was associated with a
less favorable outcome soon after LT.
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To decrease the mortality of CF patients on the WL and
to improve outcomes after LT, health authorities need to
acknowledge different aspects of the LT program, from
the shortage of suitable lung donors to organ allocation
policies. The use of marginal grafts, the reconditioning of
grafts with poor function and from donation after cardiac
death and living lobar transplant have been developed to
increase the number of LTs. The current organ allocation
policy in Italy should also be critically evaluated in relation
to the results obtained in CF subjects: disease-specific pa-
rameters should be considered for waitlist death risk and
transplant benefit to give priority to LT. A national regis-
try that is linked with the transplant centers and which
collects demographic and clinical data of all subjects at
the time of their inclusion on the waiting list, as well as
outcome after LT, is a top priority for improving the organ
allocation policy for all LT indications in Italy.
(Manuscript: “Mortality rate of patients with cystic
fibrosis on the waiting list and within one year after lung
transplantation: a survey of Italian CF Centers”)
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